Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis

This pilot study is aimed at judging the efficacy of the lead compound with a clinically relevant allergenThe relevant allergen chosen for this study is the house dust mite Dermatophagoides pteronyssinus allergenDer pLoToxTM Natural Der pfrom Indoor Biotechnologies with a low endotoxin contentEUgWe are selecting this allergen because our team has extensive prior experience with this allergen in mouse studies and has previously determined the doses required for sensitization and challengesAlternativelywe could also use the timothy grass allergen Phleum pratense allergenLoToxTM Recombinant Phl pfrom Indoor Biotechnologiesas a more relevant allergen for allergic rhinitisbut this would require additional dose response studies to determine the amounts of allergen required for both sensitization and challenges in the murine systemWe propose to investigate the efficacy of one versus two treatments of lead compoundtwo different dosesin the Der pallergen model